Biomarker

Reference ranges are established from large population studies and define statistical normalcy — usually the middle 95% of a tested population. But that population includes sick, sedentary, metabolically compromised individuals. A result at the high end of normal may still indicate impaired function when viewed in clinical context. SPOKEmed targets optimal ranges — where function, not just statistical normalcy, is the goal. A fasting insulin of 14 is technically normal but suggests significant insulin resistance; an optimal insulin is below 8.

Because standard reference ranges are built from population statistics — they define the middle 95% of a large, unselected tested population that includes metabolically compromised individuals. Being 'in range' means you are not an outlier in that population. It does not mean your biology is functioning optimally. SPOKEmed uses evidence-based optimal ranges — for example, fasting insulin below 8 mIU/L rather than the standard reference ceiling of approximately 24; A1C below 5.5% rather than below 5.7%; ApoB below 80 mg/dL rather than below 130. These distinctions routinely surface early-stage dysfunction that standard reference ranges would classify as normal and therefore dismiss.

Yes — and tracking how they change is one of the most powerful tools in clinical practice. Improvement in fasting insulin, ApoB, hs-CRP, and hormone levels over time provides objective confirmation that the protocol is working — and reveals which interventions are producing the most measurable benefit. SPOKEmed uses serial biomarker measurement at 3 to 4 month intervals during active treatment to guide protocol refinement.